248 related articles for article (PubMed ID: 21849418)
21. Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer.
Marchion DC; Xiong Y; Chon HS; Al Sawah E; Bou Zgheib N; Ramirez IJ; Abbasi F; Stickles XB; Judson PL; Hakam A; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund AE; Lancaster JM
Am J Obstet Gynecol; 2013 Dec; 209(6):576.e1-576.e16. PubMed ID: 23933223
[TBL] [Abstract][Full Text] [Related]
22. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.
Hayakawa J; Ohmichi M; Kurachi H; Kanda Y; Hisamoto K; Nishio Y; Adachi K; Tasaka K; Kanzaki T; Murata Y
Cancer Res; 2000 Nov; 60(21):5988-94. PubMed ID: 11085518
[TBL] [Abstract][Full Text] [Related]
24. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
25. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.
Stronach EA; Chen M; Maginn EN; Agarwal R; Mills GB; Wasan H; Gabra H
Neoplasia; 2011 Nov; 13(11):1069-80. PubMed ID: 22131882
[TBL] [Abstract][Full Text] [Related]
26. Ojeok-san enhances platinum sensitivity in ovarian cancer by regulating adipocyte paracrine IGF1 secretion.
Ma J; Li J; Chen X; Ma Y
Adipocyte; 2024 Dec; 13(1):2282566. PubMed ID: 37993991
[TBL] [Abstract][Full Text] [Related]
27. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
28. Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity.
Judson PL; Al Sawah E; Marchion DC; Xiong Y; Bicaku E; Bou Zgheib N; Chon HS; Stickles XB; Hakam A; Wenham RM; Apte SM; Gonzalez-Bosquet J; Chen DT; Lancaster JM
Int J Gynecol Cancer; 2012 Jul; 22(6):960-7. PubMed ID: 22740002
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
[TBL] [Abstract][Full Text] [Related]
30. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
Zhang C; Wang M; Shi C; Shi F; Pei C
Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
[TBL] [Abstract][Full Text] [Related]
31. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
Wang Y; Qu Y; Niu XL; Sun WJ; Zhang XL; Li LZ
Cytokine; 2011 Nov; 56(2):365-75. PubMed ID: 21742513
[TBL] [Abstract][Full Text] [Related]
32. MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.
Zhao H; Yu X; Ding Y; Zhao J; Wang G; Wu X; Jiang J; Peng C; Guo GZ; Cui S
Oncotarget; 2016 Aug; 7(33):53254-53268. PubMed ID: 27449101
[TBL] [Abstract][Full Text] [Related]
33. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
[TBL] [Abstract][Full Text] [Related]
34. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
35. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
[TBL] [Abstract][Full Text] [Related]
36. The clinical relevance of chemosensitivity testing in ovarian cancer.
Taylor CG; Sargent JM; Elgie AW; Reid FD; Alton PA; Hill JG
Cancer Detect Prev; 1998; 22(4):305-12. PubMed ID: 9674873
[TBL] [Abstract][Full Text] [Related]
37. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.
Bhatt M; Ivan C; Xie X; Siddik ZH
Oncotarget; 2017 Feb; 8(7):10905-10918. PubMed ID: 28038466
[TBL] [Abstract][Full Text] [Related]
38. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
39. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
40. Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.
Blessing AM; Santiago-O'Farrill JM; Mao W; Pang L; Ning J; Pak D; Bollu LR; Rask P; Iles L; Yang H; Tran S; Elmir E; Bartholomeusz G; Langley R; Lu Z; Bast RC
Cancer; 2020 Aug; 126(15):3579-3592. PubMed ID: 32484926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
